on november 27-29, 2020 china healthcare summit of entrepreneurs, scientists and investors (chsesi) was held at hangzhou international expo center. leaders of relevant national ministries and commissions, academicians of the academy of sciences, pharmaceutical entrepreneurs, scientists, and investors gathered to discuss about pharmaceutical innovation and forward-looking industrial restructuring. dr. ting xu, founder, chairman and ceo of alphamab oncology, was invited to attend the conference as a member of the presidium of the conference, and participated in dialogues to exchange with china medical innovation top 100 on the scientists leading “hang” forum.
chsesi is initiated and organized by the china pharmaceutical enterprise management association and china medicinal biotech association and it is guided by china peasants and workers democratic party central medical and health work committee, biotechnology and pharmacy work committee and youth work committee. moreover, chsesi is co-organized by e-healthcare executive and china healthcare investment 50 forum. it is the highest specifications, the strongest influence and the largest scale industrial event in china's pharmaceutical industry. a number of major awards in the pharmaceutical industry were announced at the conference, and alphamab oncology was amongst the list of "2020 chinese pharmaceutical innovative enterprises 100".
the " chinese pharmaceutical innovation enterprises 100" is evaluated based on four indicators: the number of authorized patents, the total number of patent citations, the number of clinical trials and the number of innovative drugs approved and listed, so as to select the strongest companies to represent china's pharmaceutical industry. the selected companies are the new force for china's pharmaceutical industry to participate in international competition and the important force for the transformation and upgrading of china's pharmaceutical industry to consolidate industry competitiveness.
alphamab oncology was selected for two consecutive years, demonstrating the company's innovative strength to lead the industry.
as a leading biopharmaceutical company in china, under the leadership of dr. xu ting, alphamab oncology has created a heterodimer bispecific platform (crib), a proprietary platform (cram) and other uniquely competitive technology platforms in the field of biomedicine have built a biomacromolecule industrialization base that meets international standards. the company has a fully integrated platform from the early research and development stage of innovative drugs to global clinical stage and then expand to large-scale commercial production capabilities. alphamab oncology’s pipeline includes eight anti-tumor drug candidates including mainly bi-specifics, and a covid-19 multifunctional antibody. more than 30 clinical trials of different phases have been carried out for 4 of the products under development worldwide, and multiple indications-related studies have entered registration/phase iii clinical trials, and 11 clinical trials of combination therapies have been initiated.
“innovative medicine for a better life”. technological innovation has not only changed the way people live, but also provided hope for mankind to overcome diseases and enjoy a better life. alphamab oncology will continue to focus on its original aspirations, keep its mission in mind, and use our innovative scientific research results to build a healthy chinese dream with everyone and benefit patients around the world.
alphamab oncology forward-looking statements
this press release contains statements related to our future business and financial performance and future events or developments involving alphamab oncology that may constitute forward-looking statements. these statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. these statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. we may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. in addition, our representatives may from time to time make oral forward-looking statements. such statements are based on the current expectations and certain assumptions of alphamab oncology’s management and business operation, many of which are difficult to predict and generally beyond alphamab oncology’s control. these are subject to a number of risks and uncertainties, including but not limited to, uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, alphamab oncology's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding and alphamab oncology’s disclosures. should one or more of these risks or uncertainties materialize, or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of alphamab oncology may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. other than as required by applicable law, alphamab oncology undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.